JZYY(SH:600750)2020-04-24 16:00Financial Performance - Net profit attributable to shareholders of the listed company was CNY 131,424,924.09, an increase of 3.44% year-on-year[10]. - Operating income for the first quarter was CNY 525,279,630.39, down 2.23% from the same period last year[10]. - Revenue from over-the-counter drugs was CNY 437,696,076.83, a decrease of 3.14% year-on-year[17]. - Revenue from prescription drugs increased by 21.42% to CNY 69,948,554.85[17]. - Total operating revenue for Q1 2020 was $525.28 million, a decrease of 2.3% from $537.29 million in Q1 2019[61]. - Q1 2020 total profit was approximately ¥133.95 million, a decrease of 4.7% from ¥140.27 million in Q1 2019[68]. Cash Flow - The net cash flow from operating activities increased by 87.12% to CNY 155,522,193.97 compared to the previous year[10]. - Net cash flow from operating activities for the period was 155.52 million RMB, an increase of 72.41 million RMB, representing a growth of 87.12% compared to the same period last year[26]. - Q1 2020 cash flow from operating activities was ¥155.52 million, significantly up from ¥83.12 million in Q1 2019, representing an increase of 87.0%[73]. - The total cash inflow from operating activities was ¥391,668,136.76 in Q1 2020, compared to ¥313,863,527.14 in Q1 2019, marking an increase of about 25%[75]. - The cash outflow from operating activities decreased to ¥229,909,117.78 in Q1 2020 from ¥251,735,294.02 in Q1 2019, showing a reduction of approximately 9%[75]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,691,593,477.87, a decrease of 1.42% compared to the end of the previous year[10]. - Other current assets at the end of the period amounted to 6.41 million RMB, a decrease of 50.23 million RMB, representing a decline of 88.69% compared to the end of the previous year[23]. - Accounts payable at the end of the period amounted to 33.52 million RMB, a decrease of 22.79 million RMB, representing a decline of 40.47% compared to the end of the previous year[23]. - Total liabilities decreased from 834,837,147.96 to 632,973,192.84, a decline of around 24.1%[51]. - Current liabilities decreased significantly from 748,912,845.10 to 549,372,684.08, a reduction of approximately 26.7%[49]. Shareholder Information - The total number of shareholders at the end of the reporting period was 38,411[18]. - The company aims to optimize management and enhance marketing capabilities to mitigate the impact of the pandemic on operations[12]. - The company plans to maintain operational targets despite challenges posed by the pandemic[12]. Investment and Financial Activities - The company has entrusted 50 million RMB in structured deposits with various banks, with annualized returns ranging from 1% to 3.9%[31]. - The company confirmed investment income of 150,000 RMB from entrusted loans as of the end of the reporting period[27]. - The company reported a financial expense of -4.77 million RMB, a decrease of 1.89 million RMB, representing a decline of 65.35% compared to the same period last year[26]. - Other income for the period was 2.06 million RMB, a decrease of 8.35 million RMB, representing a decline of 80.17% compared to the same period last year[26]. Research and Development - Research and development expenses for Q1 2020 were $8.80 million, down from $10.50 million in Q1 2019[61]. - Q1 2020 R&D expenses were ¥8.80 million, an increase of 19.8% compared to ¥7.35 million in Q1 2019[68].